Webinar: Driving Successful Therapeutic and Diagnostic Development: Effective Practices for Integrating Biomarkers, Biospecimens, and Science from Concept through Clinic to Cloud


In the rapidly evolving world of precision medicine, the successful integration of high-quality biospecimens and well-defined biomarkers is a fundamental aspect. Together with robust scientific methodologies and validation procedures, they drive discovery, clinical development, and the advent of Artificial Intelligence (AI)-driven diagnostics.

This webinar delves into the practical application of biospecimens in critical areas like neurodegeneration, immuno-oncology, and oncology. It outlines the development of assays for clinical application, the creation of multiplexed Immunohistochemistry (IHC) assays, and the use of sequenced biospecimens in the development and diagnosis of targeted therapies.

Key topics will also highlight the value of Tissue Microarrays (TMAs), the advantage of accessing diverse disease indications, the necessity for substantial tissue cohorts for clinical trial assay validation, and the role of tissue images (Hematoxylin & Eosin (H&E), IHC) and related sample data (Next-Generation Sequencing (NGS)) in shaping AI-based diagnostics.


Webinar: Maximizing Efficiency in Your Next State of the Art Facility Build

2023-06-20T11:58:00-04:00Cell & Gene Therapy, Events|

Sponsored by Project Farma, a Precision for Medicine Company, this panel will feature insights from industry leaders on their organization’s risk-based approaches, strategies, and regulatory, manufacturing, and commercial needs to maximize efficiency in their facility build.

This discussion will be moderated by Chad Salisbury: SVP (Project Farma), and include insights from Adam Barlow: CEO and Founder (Baseline Controls), Antinea Chair: VP, Technical Operations (Cellares), Steve Marr: Head of Capital, Real Estate, and Facilities (Spark), Matthew Smith: Head of Project Delivery (Novartis), and Sarah Stoll: Sr. Director (Project Farma).


White Paper: Gene Editing Breakthroughs: A New Hope for Patients

2023-06-20T14:19:37-04:00Cell & Gene Therapy, News, Thought Leadership|

Gene editing technology has rapidly evolved over the past decade. From the initial breakthrough of sequencing the first human genome to researchers today having the ability to create genetically modified mice in as little as four weeks. CRISPR Cas-based gene editing, which acts as a pair of genomic scissors, is at the core of these innovations. The revolutionary technology has enabled rapid genome sequencing and editing to spur advancements in disease research and treatment.

In this white paper, Anshul Mangal President of Project Farma and Precision ADVANCE and Cynthia Pussinen, Advisor & Executive Consulting Partner share how the latest breakthroughs in gene editing technology have the potential to dramatically improve outcomes for patients.


White Paper: Moving CGTx Clinical Development Forward in 2023

2023-06-20T14:21:24-04:00Cell & Gene Therapy, Thought Leadership|

Clinical trials are foundational to developing innovative, life-saving treatments and cures for patients. For developers of cell and gene therapy (CGTx) products, the path to clinical success is fraught with vast and complex challenges. The CGTx field is becoming more crowded, with increased clinical trial volume and an influx of less-experienced sponsors contributing to an increase in clinical holds in the category. Such challenges intensify the pressure to succeed in a fiercely competitive environment.


White Paper: Market Trends and Expectations for Advanced Therapies in 2023

2023-07-06T11:12:25-04:00Cell & Gene Therapy, Thought Leadership|

The cell and gene therapy space has undergone transformational change in the last few years, driven by the promise these modalities have demonstrated in addressing rare and intractable diseases. Achievements in the CAR-T therapy space – there are now six approved CAR-T treatments on the market – in conjunction with breakthroughs in gene therapy and viral vector drugs, have signaled a new era of innovation aimed at furthering cell and gene therapies within the greater healthcare landscape.


On-Demand: Cell & Gene Day, 2023

2023-07-10T12:09:50-04:00Cell & Gene Therapy, Events|

Even as cell and gene therapies inspire hope for patients who previously had none, the path to commercialization is littered with roadblocks. There is a pressing need for increased efficiency, enhanced safety, and innovative approach to pricing and access. How are leading CGTx innovators approaching these challenges?  Find out at Cell & Gene Day 2023, a free virtual event, streaming on demand HERE.


On Demand: Cell and Gene Therapies – How High Can Prices Go?

2023-07-18T16:07:02-04:00Cell & Gene Therapy, Events, Thought Leadership|

Join our experts on April 26, 2023 at 9AM EST as we dive into a powerful 30 minute webinar followed by live Q&A.

This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).


Precision for Medicine Expands Advanced Tissue Profiling and Genomic Capabilities with new Houston Laboratory

2023-04-10T16:49:19-04:00News, Press Releases|

Houston is one of seven global Precision specialty labs addressing the rising demand for rapid, comprehensive biomarker data to support the development of advanced therapies and diagnostics

HOUSTON, Tx., April 12, 2023 – Precision for Medicine, the first global biomarker-driven clinical research organization, today announced the expansion of its cell biology and genomics laboratory in Houston, TX, proliferating the company’s global biomarker capabilities and laboratory operations.


White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions

2023-06-26T16:42:51-04:00Cell & Gene Therapy, News, Thought Leadership|

Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.


Conference: Gene Therapy for Rare Disorders (GTRD), 2023

2023-03-14T10:37:26-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s Gene Therapy for Rare Disorders on March 20-23, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below. 

  • Precision ADVANCE will have a plenary speaking position on March 21, 2023, 8:30 – 9:00 am.
  • Project Farma will be facilitating a plenary panel discussion ” Current Trends in Technical Operations for Rare Disorders” on March 21, 2023, 10:45 – 11:15 am.
  • Project Farma’s Tony Khoury (EVP, Project Farma) will be joining the Manufacturing track panel discussion, “Capacity versus Capability – Moving Towards Innovative Manufacturing Processes,” on March 21, 2023, 11:15 – 11:45 am.
  • Precision ADVANCE will hold a drinks reception on March 21, 2023, at 6:10 pm in the Grand & Liberty Ballroom.

Connect with our Advanced Therapy experts

  • Visit us at booth 13 in the exhibition area
  • Schedule in-person or virtual meetings by clicking here: https://bit.ly/precisionmedicinegrp
  • Attend our ADVANCE-sponsored Drinks Reception on March 21, 2023, at 6:10 PM ET

Plenary Speaking Position: Successfully Launching a Gene Therapy with Cynthia Pussinen & Dave Lennon
Precision ADVANCE | March 21, 2023, 8:30 – 9AM ET 

  • Key Takeaways
    • Identify active strategies to enable a smooth plan from preclinical development to commercialization
    • New approaches for regulatory approval and commercialization
    • Anticipating and overcoming potential hurdles specific to gene therapies
    • The future of the industry


  • Anshul Mangal: President (Project Farma & Precision ADVANCE)
  • Cynthia Pussinen: Former CTO (Spark Therapeutics Inc.)
  • Dave Lennon: CEO (Satellite Bio)

Panel Discussion: Current Trends in Technical Operations for Rare Disorders
Project Farma | March 21, 2023, 10:45-11:15AM ET

  • Key Takeaways
    • Current trends impacting manufacturing of gene therapies including capital markets, supply chain and technologies
    • Shifts in technical operations as a result of current trends
    • Opportunities and innovations in technical operations that can transform the industry


  • [Moderator] Charlie Harper: Vice President, Consulting (Project Farma)
  • Greg Gara: Senior Vice President (Project Farma)
  • Tony Khoury: Executive Vice President (Project Farma)
  • Eric Hacherl: Vice President, Manufacturing (Spark Therapeutics, Inc.)

Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Project Farma | March 21, 2023, 11:15 – 11:45AM ET

  • Greg Gara: Senior Vice President (Project Farma) to join
Load More Posts